UBS Oncology Impact Fund L.P., 10% Owner at Werewolf Therapeutics, Inc. (HOWL), sold 386,389 shares at $1.18 ($438K) on 2025-11-10, disclosed to the SEC on 2025-11-12.
Scheduled sale ($438k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.11 | 68,480 | $76K | 17.3% |
| 2 | $1.11 | 68,480 | $76K | 17.3% |
| 3 | $1.18 | 48,570 | $57K | 13.1% |
| 4 | $1.18 | 48,570 | $57K | 13.1% |
| 5 | $1.14 | 55,810 | $64K | 14.5% |
| 6 | $1.14 | 55,810 |
| $64K |
| 14.5% |
| 7 | $1.09 | 40,669 | $44K | 10.1% |
| Total | $1.13 avg | 386,389 | $438K | 100% |
| Filing → |
| ITOS | SELL | 2021-09-27 | $3.2M | — | Filing → |
| CGEM | SELL | 2021-09-02 | $1.3M | — | Filing → |
| HARP | SELL | 2021-05-24 | $541K | — | Filing → |